Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World Journal of Hepatology. Feb 27, 2020; 12(2): 34-45
Published online Feb 27, 2020. doi: 10.4254/wjh.v12.i2.34
Published online Feb 27, 2020. doi: 10.4254/wjh.v12.i2.34
Clinical characteristics and treatment outcomes in patients with liver cirrhosis and lymphoma
José A González-Regueiro, Astrid Ruiz-Margáin, Mariana Cruz-Contreras, Ana M Montaña-Duclaud, Andrea Cavazos-Gómez, Ricardo U Macías-Rodríguez, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14080, Mexico
Roberta Demichelis-Gómez, Department of Hematology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14080, Mexico
Author contributions: González-Regueiro JA and Ruiz-Margáin A contributed equally to this article; González-Regueiro JA, Demichelis-Gómez R, Ruiz-Margáin A and Macías-Rodríguez RU contributed to study conception and design; González-Regueiro JA, Cruz-Contreras M, Montaña-Duclaud AM and Cavazos-Gómez A contributed to acquisition of clinical data from medical records; Ruiz-Margáin A and Macías-Rodríguez RU performed the analysis of data and contributed with critical revisions for the content of the manuscript; González-Regueiro JA, Cruz-Contreras M, Montaña-Duclaud AM, Cavazos-Gómez A, Demichelis-Gómez R, Ruiz-Margáin A and Macías-Rodríguez RU contributed to interpretation of data and writing the final version of the article to be published.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) (Ref. No. “2914”).
Informed consent statement: Given the retrospective design of this study, patients were not required to provide informed consent as the data was obtained from medical records after the completion of treatment.
Conflict-of-interest statement: All authors declare no conflicts of interest related to this article.
Data sharing statement: No additional data are available.
STROBE statement: The guidelines of the STROBE statement have been adopted.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ricardo U Macías-Rodríguez, MD, MSc, PhD, Assistant Professor, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14080, Mexico. ricardomacro@yahoo.com.mx
Received: September 10, 2019
Peer-review started: September 10, 2019
First decision: September 26, 2019
Revised: November 21, 2019
Accepted: December 19, 2019
Article in press: December 19, 2019
Published online: February 27, 2020
Processing time: 169 Days and 15.2 Hours
Peer-review started: September 10, 2019
First decision: September 26, 2019
Revised: November 21, 2019
Accepted: December 19, 2019
Article in press: December 19, 2019
Published online: February 27, 2020
Processing time: 169 Days and 15.2 Hours
Core Tip
Core tip: Treatment in patients with liver cirrhosis and lymphoma represents a challenge for physicians given the lack of scientific evidence. Experts recommend offering oncological treatment only to patients with compensated cirrhosis. In this study, we included mainly decompensated patients with cirrhosis and lymphoma, and when compared to patients with lymphoma, we observed that clinical characteristics, response rate and complications derived from chemotherapy were similar in both groups. Chemotherapy was adjusted more in patients with liver dysfunction; however, this did not alter the response to treatment or prognosis. We propose that lymphoma treatment can be provided in patients with cirrhosis at any clinical state.